From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs
- 16 January 2020
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 15 (5) , 430-448
Abstract
The orexin system is responsible for regulating the sleep‐wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5‐methoxy‐4‐methyl‐2‐[1,2,3]triazol‐2‐yl‐phenyl)‐{(S)‐2‐[5‐(2‐trifluoromethoxy‐phenyl)‐[1,2,4]oxadiazol‐3‐yl]‐pyrrolidin‐1‐yl}methanone (6), a compound which emerged from our in‐house research program. Compound 6 was shown to be a potent, brain‐penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above‐mentioned shortcomings resulted in the identification of (4‐chloro‐2‐[1,2,3]triazol‐2‐yl‐phenyl)‐{(S)‐2‐methyl‐2‐[5‐(2‐trifluoromethoxy‐phenyl)‐4H‐[1,2,4]triazol‐3‐yl]‐pyrrolidin‐1‐yl}l‐methanone (42), a DORA with improved in vivo efficacy compared to 6.Keywords
This publication has 19 references indexed in Scilit:
- Sleep modulating agentsBioorganic & Medicinal Chemistry Letters, 2019
- Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administrationEuropean Neuropsychopharmacology, 2019
- The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomniaJournal of Psychopharmacology, 2019
- The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468The Journal of Pharmacology and Experimental Therapeutics, 2017
- Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to ManScientific Reports, 2016
- Suvorexant: The first orexin receptor antagonist to treat insomniaJournal of Pharmacology and Pharmacotherapeutics, 2015
- Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor AntagonistJournal of Medicinal Chemistry, 2015
- Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?International Journal Of Clinical Practice, 2014
- Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic useFrontiers in Neuroscience, 2014
- SB‐334867‐A: the first selective orexin‐1 receptor antagonistBritish Journal of Pharmacology, 2001